PMID: 6369480Jan 1, 1984

The acylampicillins: mezlocillin, piperacillin, and azlocillin

Reviews of Infectious Diseases
G L DrusanoW L Hewitt

Abstract

The new acylampicillin derivatives azlocillin, mezlocillin, and piperacillin have an increased activity against many gram-negative bacilli, especially Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa, when compared with the carboxypenicillins carbenicillin and ticarcillin. The new penicillins show synergistic activity in combination with aminoglycosides but, when combined with other beta-lactams, may be synergistic (piperacillin and moxalactam; mezlocillin and cefoperazone), indifferent, or antagonistic (azlocillin, mezlocillin, or piperacillin and cefoxitin or cefamandole). The in vitro activity of these agents, either alone or in combination, appears to correlate with in vivo efficacy in animal models. The new penicillins are clinically effective for a very broad range of infections, including life-threatening nosocomial infections. Adverse effects with these, as with other semisynthetic penicillins, are minimal. Attention must be paid to the potential for infection by naturally resistant, gram-negative bacilli such as beta-lactamase-producing Escherichia coli and for the emergence of resistance during therapy. The granulocytopenic patient should receive these agents only in conjunction with another agen...Continue Reading

Citations

Jan 1, 1987·Cancer Metastasis Reviews·K H Mayer, S M Opal
Jan 1, 1993·European Journal of Clinical Pharmacology·M DuponJ Saric
Jan 1, 1985·Pharmacology & Therapeutics·R B SykesE A Swabb
Jul 1, 1985·Pediatric Neurology·W E Bell, G A McGuinness
May 1, 1985·Antimicrobial Agents and Chemotherapy·B A ZajacR R MacGregor
May 1, 1986·Antimicrobial Agents and Chemotherapy·P A ColaizziL A Beightol
May 1, 1990·Antimicrobial Agents and Chemotherapy·S L BarriereR W Frost
Aug 1, 1987·The American Journal of the Medical Sciences·S MilsteenM R Heyman
Feb 1, 1988·American Journal of Obstetrics and Gynecology·R D AlvarezJ F Huddleston
Jun 7, 1985·The American Journal of Medicine·R A SalataR J Duma
Dec 1, 1990·Journal of the American Geriatrics Society·T T Yoshikawa
Feb 18, 1988·The New England Journal of Medicine·G R Donowitz, G L Mandell
Sep 1, 1985·Journal of Surgical Oncology·Z LandoyL E Blumenson
Apr 1, 1985·Infection Control : IC·S M Norris
Jul 1, 1986·Drug Intelligence & Clinical Pharmacy·S L Barriere

Related Concepts

Agranulocytosis
Azlin
Bacterial Infections
Mefoxin
Pulmonary Cystic Fibrosis
Melocin
Malignant Neoplasms
Penicillin
Piperacillin-ratiopharm

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.